ROCKVILLE, Md.--(EON: Enhanced Online News)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to announce the winner of their Cancer Discovery Incubator Award, Midissia Therapeutics (Midissia). Midissia is a clinical stage immunotherapy start-up focused on immune intensification.
“We are thrilled to provide Midissia with a place to grow here in Maryland and look forward to watching their technology advance and benefit future patients.”
Currently, Midissia is based in San Francisco and incorporated in Delaware. Immunomic Therapeutics’ Cancer Discovery Incubator will provide Midissia with the opportunity to develop a proof-of-concept experiment in the Immunomic laboratories. Additionally, Midissia will receive funding, lab equipment and a unique mentorship with the Immunomic executive team for one year.
“A number of extremely impressive companies applied for our incubator opportunity. The Midissia technology was chosen because it addresses a specific area of need in cancer treatment and the technology and entrepreneur wowed our selection committee,” said Bill Hearl, CEO of Immunomic. “We are thrilled to provide Midissia with a place to grow here in Maryland and look forward to watching their technology advance and benefit future patients.”
Midissia Therapeutics is developing personalized dendritic cancer vaccines that have the potential to significantly impact the overarching problems of toxicity, drug resistance and recurrence that plague current modalities of cancer treatment.
“We are honored to receive this tremendous recognition for our work,” said Midissia President and CEO Tania Fernandez. “The Cancer Discovery Incubator will allow us to continue to expand our company and technology. We look forward to learning from Immunomic executives and altering the vaccine space.”
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with Astellas Pharma Inc. to explore the use of LAMP-Vax, an immunotherapy platform, for use in the prevention and treatment of allergic diseases. For information about ITI and LAMP Technology, visit www.immunomix.com.
Midissia Therapeutics (Midissia) is an immuno-oncology start-up developing autologous dendritic cancer vaccines. Midissia is focused on a strategy of immune intensification with the objective of optimizing the anti-tumor response seen with the AdHER2 vaccine by combining it with check-point inhibitors. The AdHER2 vaccine is currently in phase one clinical trials.